Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 342 participants.

Also called NCT05714085

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 342 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05714085
  • EU CT 2022-501238-52-00
  • WHO UTN U1111-1275-1768
  • EudraCT 2021-004399-33
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Malaysia, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05714085. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-31 (actual); primary completion 2029-08-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Condition
Heart Failure
Condition
Left Ventricular Systolic Dysfunction
Intervention (Drug)
Vericiguat tablet
Intervention (Drug)
Vericiguat suspension
Intervention (Drug)
Placebo tablet
Intervention (Drug)
Placebo suspension
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct05714085
Content hash
1b6cd7aa5e5c89f487939e0fcd5b16db6761faee2afa49e19699630d77971c59